The Most Common Myths About HBOT: What the Evidence Actually Says

Hyperbaric oxygen therapy occupies an unusual position in medicine. It has a well-established clinical track record for a defined set of conditions, a growing body of research in emerging areas, and a consumer market that has generated a volume of misinformation that makes it genuinely difficult to know what to believe.

The myths that circulate around HBOT tend to fall into two camps. Some overstate what the therapy can do, turning it into a cure-all that the evidence does not support. Others dismiss it entirely, treating it as pseudoscience despite decades of clinical use and peer-reviewed research. Neither position is accurate, and both cause harm, one by raising false expectations, the other by steering people away from a therapy that may genuinely help them.

What follows is a clear-eyed look at the claims that come up most often, and what the evidence actually says.

Myth: HBOT Can Cure Almost Any Condition

This is the most pervasive myth in the consumer HBOT market, and it is largely a product of aggressive marketing.

HBOT has a well-documented evidence base for a specific set of indications. These include diabetic foot wounds, decompression sickness, carbon monoxide poisoning, radiation tissue damage, certain serious infections, and a range of other conditions where the research is both substantial and consistent. For these applications, HBOT is not experimental, it is an established clinical intervention with defined protocols and measurable outcomes.

Beyond that core evidence base, there is a broader landscape of emerging research. Studies in neurological recovery, traumatic brain injury, long COVID, and other areas are producing results that are genuinely interesting and, in some cases, compelling. This research is ongoing, and the picture is still developing.

What HBOT is not is a universal treatment for every condition it is marketed for. Claims that it cures cancer, reverses ageing, eliminates autism, or resolves conditions for which no credible research exists are not supported by the evidence. They are marketing claims, and treating them as clinical facts does a disservice to people making serious decisions about their care.

The honest position is that HBOT has strong evidence for some conditions, promising but preliminary evidence for others, and no credible evidence for a number of the claims made in the consumer market.

Myth: HBOT Is Pseudoscience With No Real Evidence Base

The opposite myth is equally wrong, and it tends to come from people who have encountered the overclaiming end of the market and concluded that the entire field is suspect.

HBOT is not pseudoscience. It is a physiological intervention with a clear mechanism of action, increasing the partial pressure of oxygen in the blood plasma, which allows oxygen to reach tissues that red blood cells cannot easily access, and a substantial body of peer-reviewed research supporting its use for specific conditions.

The Undersea and Hyperbaric Medical Society (UHMS) and the European Committee for Hyperbaric Medicine (ECHM) both publish clinical guidelines for HBOT based on systematic reviews of the evidence. These are not fringe organisations. They represent the mainstream of hyperbaric medicine, and their guidelines reflect decades of clinical research.

The confusion arises because the consumer HBOT market has attached itself to the clinical evidence base in ways that are not always accurate. The fact that some HBOT marketing is misleading does not mean that HBOT itself lacks evidence. It means that the marketing should be read critically, not that the therapy should be dismissed.

Myth: Any Hyperbaric Chamber Delivers the Same Benefits

This myth is responsible for a significant amount of wasted money and misaligned expectations.

The pressure at which HBOT is delivered is the single most important variable in the therapy. The clinical evidence base for HBOT was built almost entirely on research conducted in hard shell chambers at pressures of 2.0 ATA and above. The physiological effects that make HBOT clinically meaningful, the dissolution of oxygen into blood plasma at concentrations that produce therapeutic effects, are pressure-dependent. They do not occur to the same degree at 1.3 ATA.

Soft shell chambers, which typically operate between 1.3 and 1.5 ATA, are a different intervention. They may offer genuine benefits for wellness and recovery applications, and many people find them useful for those purposes. But they cannot replicate the clinical effects of hard shell HBOT at 2.0 ATA or higher. Using a soft shell chamber as a substitute for a prescribed clinical protocol is not a meaningful approximation.

The chamber type also affects oxygen delivery. Most soft shell chambers are pressurised with ambient air, not pure oxygen. Some allow for an oxygen concentrator to be connected, which increases the fraction of inspired oxygen, but the combination of lower pressure and lower oxygen concentration produces a fundamentally different physiological environment than a clinical hard shell chamber.

Understanding this distinction before purchasing a chamber or booking a course of sessions is essential.

Myth: HBOT Is Dangerous

HBOT has a well-established safety profile when administered correctly, in appropriate equipment, at appropriate pressures, with proper clinical oversight.

The risks that exist are real but manageable. Ear and sinus barotrauma, discomfort or injury caused by pressure changes, is the most common side effect, and it is generally mild and preventable with proper technique. Oxygen toxicity is a risk at high pressures and long durations, but it is well understood and managed through protocol design. Fire risk exists in oxygen-enriched environments and is addressed through engineering standards and operational protocols in clinical settings.

The safety concerns that are sometimes raised about HBOT tend to conflate two different contexts. In a properly equipped clinical facility, with trained staff and appropriate equipment, HBOT has a strong safety record. In a home setting, with a consumer-grade soft shell chamber used without clinical oversight, the risk profile is different, not because the therapy is inherently dangerous, but because the safety infrastructure of a clinical environment is absent.

The appropriate response to this distinction is not to avoid HBOT. It is to understand the context in which it is being used and to ensure that the equipment and oversight are appropriate for the application.

Myth: More Sessions Always Means Better Results

This is a myth that benefits clinics commercially and harms patients practically.

HBOT protocols are designed around specific parameters, pressure, duration, and session count, that have been validated in clinical research. For the conditions with the strongest evidence base, those parameters are reasonably well defined. Departing significantly from them, including by adding sessions beyond the validated range, does not necessarily improve outcomes and may not be clinically justified.

There is also a phenomenon known as oxygen toxicity that becomes relevant at high cumulative doses. The body's response to elevated oxygen concentrations is not linear, and there are diminishing returns, and potential adverse effects, associated with excessive exposure.

A well-designed HBOT protocol includes defined outcome measures and decision points. A thoughtful clinician will assess whether a patient is responding as expected and adjust accordingly, rather than simply continuing sessions indefinitely. If a clinic's recommendation is primarily driven by session count rather than clinical rationale, that is worth examining carefully.

Myth: HBOT Is Only for Serious Medical Conditions

The clinical evidence base for HBOT is concentrated in serious medical conditions, but that does not mean the therapy has no value outside that context.

A growing number of people use HBOT for wellness, recovery, and performance applications, areas where the formal evidence is less developed but where the volume of anecdotal experience is substantial. Athletes using HBOT to accelerate recovery between training sessions, individuals using it as part of a longevity or cognitive performance protocol, and people seeking general wellness benefits are all using the therapy in ways that fall outside the traditional clinical framework.

These applications are not fraudulent. They reflect a genuine interest in the physiological effects of elevated oxygen at pressure, applied to goals that are not defined by a specific medical diagnosis. The evidence base for these uses is less formalised, but it is not absent, and the research in areas like athletic recovery and cognitive performance is active and growing.

The honest position is that HBOT has well-established clinical applications and a broader range of wellness applications where the evidence is promising but less definitive. Both are legitimate uses of the therapy, and neither should be dismissed.

Myth: You Need a Prescription to Access HBOT

This depends entirely on the context and the jurisdiction.

In a clinical setting, HBOT for a specific medical indication is typically delivered under medical supervision, and in many cases a referral or prescription is part of the process. This is appropriate, clinical HBOT involves pressures and protocols that warrant medical oversight.

In the wellness and consumer market, access to HBOT is generally not restricted by prescription requirements. Soft shell chambers can be purchased and used at home without a prescription. Many wellness clinics offer HBOT sessions without requiring a referral.

The relevant question is not whether you need a prescription, but whether the context in which you are accessing HBOT is appropriate for your goals. For a specific clinical indication, medical supervision is not just a regulatory requirement, it is genuinely valuable. For general wellness use, the oversight requirements are different.

Understanding the distinction between clinical and wellness HBOT, and accessing each in the appropriate context, is more useful than a blanket statement about prescription requirements.

Myth: All HBOT Clinics Are Essentially the Same

This is perhaps the most practically consequential myth on this list.

The quality of HBOT clinics varies enormously. The differences include the type and condition of the equipment, the pressure range available, the clinical expertise of the staff, the rigour of the protocols used, the quality of the patient assessment process, and the degree to which the clinic's recommendations are driven by clinical evidence rather than commercial considerations.

A clinic with a hard shell chamber capable of 2.4 ATA, staffed by physicians with formal training in hyperbaric medicine, following UHMS-aligned protocols, is a categorically different environment from a wellness centre with a soft shell chamber at 1.3 ATA, staffed by practitioners without specialist hyperbaric training, offering packages designed around commercial rather than clinical logic.

Both may describe themselves as offering HBOT. The therapy they are delivering is not the same.

Evaluating a clinic before committing to a course of treatment, understanding the equipment, the staff qualifications, the protocols, and the clinical rationale for their recommendations, is not excessive due diligence. It is the minimum reasonable standard for a therapy that involves a meaningful time and financial commitment.

A Note on Navigating the Information Landscape

The volume of misinformation around HBOT is a genuine problem. It makes it harder for people with legitimate clinical needs to find accurate information, harder for people exploring wellness applications to form realistic expectations, and harder for anyone to evaluate the claims made by clinics and chamber manufacturers.